Title: In-hospital Outcomes of Septal Myectomy Versus Alcohol Septal Ablation

for Hypertrophic Cardiomyopathy with Outflow Tract Obstruction - An Update and

Insights from The National Inpatient Sample from 2011-2019

Authors: Karla Inestroza, M.D.^a, Ivan Mijares-Rojas, M.D.^a, Carlos Matute-Martínez,

M.D.^b, Ian Ergui M.D.^a, Michael Albosta, M.D.^a, Carlos Vergara-Sanchez M.D.^c, Michael

Dangl M.D.a, Rafael Jaciel Hernandez M.D.a, Bertrand Ebner M.D.d, Louis T Vincent

M.D.^d, Jelani Grant M.D.^e, Jennifer Maning M.D.^f, Carlos Alfonso M.D.^g, Rosario

Colombo M.D.⁹.

a Internal Medicine Residency Program, University of Miami/ Jackson Memorial

Hospital

b Cardiovascular Diseases Fellowship, Division of Cardio-oncology, Yale School of

Medicine

c Internal Medicine Residency Program, University of Miami/ John F. Kennedy Medical

Center

d Cardiovascular Diseases Fellowship, University of Miami/ Jackson Memorial Hospital

e Cardiovascular Diseases Fellowship, Johns Hopkins Hospital

f Cardiovascular Diseases Fellowship, Northwestern Hospital

g Cardiovascular Medicine Division, University of Miami/ Jackson Memorial Hospital

Short Title: Outcomes of Septal Reduction Therapies in HCM

Address for correspondence:

Author: Karla Inestroza, M.D.

E-mail: karlainestroza@hotmail.com

Address: 2115 SW 3rd Ave, Apt 7

Miami, FL, 33129

Phone number: (505) 218 5337

Total word count: 3,915

Abstract

Background: Septal Myectomy (SM) and Alcohol Septal Ablation (ASA) improve symptoms in patients with Hypertrophic Cardiomyopathy with outflow tract obstruction

(oHCM). However, outcomes data in this population is predominantly from specialized

centers.

Methods: The National Inpatient Database was gueried from 2011- 2019 for relevant

ICD-9 and -10 diagnostic and procedural codes. We compared baseline characteristics

and in-hospital outcomes of patients with oHCM who underwent SM vs. ASA. A p-value

< 0.001 was considered statistically significant.

Results: We identified 17,245 patients with oHCM who underwent septal reduction

therapies, of whom 62.5% underwent SM, and 37.5% underwent ASA. Patients who

underwent SM had higher all-cause mortality (OR:2.2 [1.7-2.9]), post-procedure

ischemic stroke (OR: 2.4 [1.8-3.2]), acute kidney injury (OR: 1.9 [1.7-2.2]), vascular

complications (OR: 4 [2.8-5.7]), ventricular septal defect (OR: 4.6 [3.5-6.1]), cardiogenic

shock (OR: 2 [1.5-2.6]), sepsis (OR: 5.2 [3.3-8.1]), and left bundle branch block (OR: 3.2

[2.8-3.7]), compared to ASA. Patients who underwent ASA had higher post-procedure

complete heart block (OR: 1.2 [1.1-1.4]), 2nd-degree AV Block (OR: 2 [1.4-3]), right

bundle branch block (OR: 6.4 [5.3-7.8]), ventricular tachycardia (OR:2 [1.8-2.3]),

supraventricular tachycardia (OR: 1.4 [1.2-1.7]), and more commonly required

pacemaker (OR: 1.4 [1.2-1.6]) or implantable cardioverter-defibrillator insertion (OR: 1.3

1

[1.1-1.5]) (p<0.001 for all) compared to SM.

Conclusions: This nationwide analysis evidenced that patients undergoing SM had higher in-hospital mortality and periprocedural complications than ASA; however, those undergoing ASA had more post-procedure conduction abnormalities and pacemaker or ICD implantation. The implications of these findings warrant further investigation regarding patient selection strategies for these therapies.

Introduction

Hypertrophic cardiomyopathy (HCM) is the most common inheritable heart disease, with an approximate prevalence of 1 case in 500 persons in the general population. In the past 50 years, its perception in the cardiovascular field has changed from a rare, untreatable condition with an obscure prognosis to a disease with multimodal therapeutic approaches and a heterogeneous clinical presentation. HCM is inherited in an autosomal dominant pattern with mutations involving genes encoding proteins of the

contractile myofilament apparatus.² Histopathologically, it is identified by cardiomyocyte

hypertrophy, disarray, and increased fibrosis.³

Clinical presentation includes sudden cardiac death (SCD), sometimes as the initial manifestation, chronic Atrial Fibrillation (A. Fib), and symptomatic Heart Failure (HF), with many patients having a degree of left ventricular outflow tract obstruction (LVOTO).¹

The current therapeutic approach emphasizes SCD prevention with an implantable cardiac defibrillator (ICD).^{1,4,5} Progressive heart failure symptomatology is treated with lifestyle modifications to avoid hemodynamic LVOTO and atrioventricular nodal blocking agents (beta-adrenergic and calcium channel blockers) or disopyramide in exceptional cases.^{4,6}

Septal reduction therapy (SRT) is the next available option for a particular subset of patients that are refractory to drug therapy with a left ventricular outflow tract (LVOT) gradient ≥50 mmHg (at rest or provoked) and impaired quality of life.^{7,1} The surgical approach with Septal Myectomy (SM) reduces the degree of LVOTO and improves

cardiac function and prognosis.^{4,5,7,8} However, the less invasive interventional approach with Alcohol Septal Ablation (ASA) has also proved to be a safe alternative for patients with high surgical risk, and both procedures have a Class 1 recommendation as per the 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy.^{4,5}

The present study compared available data from the National Inpatient Sample (NIS) to illuminate safety endpoints and outcomes between SRT modalities.

Methods

Data Source

The NIS offers the largest database of hospitalizations, including data on approximately 7-8 million discharges per year and representing a 20% random and stratified sample of hospital discharges in the United States. Annual data quality assessments of the NIS are performed, guaranteeing the database's internal validity. We used the International Classification of Diseases Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases Tenth Revision, Clinical Modification (ICD-10-CM) diagnostic and therapeutic procedure codes to identify the study population. Institutional review board approval was not needed as all patient information is de-

Data Disclosure

identified within the NIS.

All the data under NIS are publicly available. Detailed ICD diagnostic and procedural codes used for statistical analyses are presented under the Data Supplement, which can be used to replicate our results.

Study Population

We performed a retrospective analysis using the NIS database from January 1, 2011, to December 31, 2019. We identified all patients aged≥18 with a diagnosis of HCM with outflow tract obstruction (oHCM) using the International ICD-9-CM Revision-Diagnostic Coding System code 425.11 or ICD-10-CM Revision-Diagnostic Coding System code

I42.1 in any of the first ten diagnostic fields, identifying a total of 51,877 cases. Then, we proceeded to identify patients who underwent SM using the International ICD-9-CM Revision-Procedure Coding System code 37.33 or ICD-10-CM Revision-Procedure Coding System code 02BM, 02BM0, 02BM0Z, and 02BM0ZZ in any of the first five diagnostic fields, and patients who underwent ASA using international ICD-9-CM Revision-Procedure Coding System code 37.34 or ICD-10-CM Revision-Procedure Coding System code 025M3, 025M3Z, 025M3ZZ, 02583, 02583Z, or 02583ZZ in any of the first five diagnostic fields. Our final study cohort comprised 17,245 patients with oHCM who underwent either SM (10,781 patients) or ASA (6,464 patients). International Classification of Diseases coding for comorbidities and post-SRT (SM or ASA) complications are listed in Table 1 in the Data Supplement.

Outcome Measures

Our primary outcome was post-SRT (SM or ASA) all-cause In-hospital mortality.

Secondary outcomes of interest were post-procedure complications with cardiac arrest, ischemic stroke, cardiogenic shock, acute kidney injury (AKI), sepsis, major vascular complications (aortic dissection, aortic aneurysm, postoperative deep vein thrombosis [DVT] or pulmonary embolism [PE]), bleeding, need for insertion of a pacemaker or ICD, cardioversion, conduction abnormalities (complete heart block, 2nd-degree atrioventricular block, and left or right bundle branch block), and arrhythmias (Ventricular fibrillation/flutter, Ventricular tachycardia, Supraventricular Tachycardia [SVT]) for indexed hospitalizations during which patients underwent SM or ASA.

Statistical Analysis

As the Agency for Healthcare Research and Quality recommended, weighted data were used for all statistical analyses. Baseline characteristics and post-procedure outcomes were compared using the Pearson Chi-Squared (χ^2) tests for categorical variables and Independent Sample T-testing for continuous variables. A p-value <0.001 was considered statistically significant.

Multivariate logistic regression was used to estimate adjusted odds ratios (aOR) and 95% confidence intervals (95% CI) to determine the association between oHCM and post-SRT (SM vs. ASA) mortality and In-hospital outcomes. All multivariate logistic regression models were created using generalized estimating equations. Our models were adjusted for age, sex, race, and statistically significant comorbidities (HTN, A. Fib, Atrial Flutter, Tobacco use, Substance use, Heart HF, Obesity, PAD, CKD, Chronic Obstructive Pulmonary Disease (COPD), prior history of Myocardial Infarction [MI], history of Percutaneous Coronary Intervention [PCI], history of Coronary Artery Bypass Graft [CABG], prior presence of Pacemaker or ICD, and Pulmonary Hypertension [PH]) between groups. As recommended by Healthcare Cost and Utilization Project, missing data for age, gender, and race were handled using multiple imputations. All statistical analyses were performed using SPSS (IBM SPSS Statistics for Mac, Version 23.0. Armonk, NY: IBM Corp.).

Results

Baseline Patient Characteristics

We identified 17,245 patients with oHCM who underwent septal reduction procedures during the years 2011-2019, of whom 10,781 (62.5%) underwent SM and 6,464 (37.5%) underwent ASA. The average age of the cohort was 60.5 years ± 14.1 years, with a median age of 62 years, ranging from 18 to 92 years. The female sex accounted for 45% (7,764) of the total population. Regarding race, white individuals accounted for the majority (82.3%) of the total population.

All comparisons henceforth are reported as SM versus (vs.) ASA for consistency. Individuals who underwent SM were younger 58.9 ± 14.1 years vs. 63.3 ± 13.6 years (p<0.001), had a lower prevalence of A. Fib (43% vs. 47.3%, p<0.001), Atrial Flutter (6.4% vs. 18.9%, p<0.001), and of prior presence of a pacemaker (3.3% vs. 8.1%, p<0.001) or ICD (12.5% vs. 20%, p<0.001), lower history of prior stroke (3.95% vs. 7.8%, p<0.001), CKD (10.5% vs. 12.5%, p<0.001), COPD (10.9% vs. 13.2%, p<0.001), history of prior MI (4.4% vs. 6.4%, p<0.001), history of previous PCI (6% vs. 9.8%, p<0.001) and prior CABG (1.2% vs. 2.2%, p<0.001) compared to those who underwent ASA.

Conversely, those who underwent SM had higher rates of tobacco use (37.3% vs. 30.8%, p<0.001), alcohol use (2.3% vs. 1.3%, p<0.001), and substance use (1.5% vs. 0.7%, p<0.001), and higher prevalence of obesity (29.2% vs. 19%, p<0.001), more HF (42.5% vs. 39.6%, p<0.001), more CAD (35.9% vs. 34.7%, p<0.001), more PAD (4%)

vs. 2.6%, p<0.001), and more PH (14.1% vs. 9.9%, p<0.001) compared to those who underwent ASA.

There was no statistically significant difference in sex between groups, with the female gender compromising 44.6% vs. 45.8% (p=0.118) of the population undergoing SM vs. ASA respectively. The incidence of HTN (72% vs. 72.2%, p=0.960), DM (17.7% vs. 18.8%, p=0.055), Hyperlipidemia (HLD, 57.2% vs. 57.7%, p=0.508), Obstructive Sleep Apnea (OSA, 20.4% vs. 20.9, p= 0.468), and liver disease and cirrhosis (2.5% vs. 3.1%, p=0.014) was not statistically different between the compared groups.

In-hospital outcomes and procedural complications

In regards to inpatient post-procedure complications, patients who underwent SM had higher rates of post-procedure ischemic stroke (2.25% vs. 1.2%, p<0.001; aOR:2.4 [95% CI:1.8-3.2]), AKI (11.5% vs. 7.3%, p<0.001; aOR:1.9 [95% CI:1.7-2.2]), VSD (4.8% vs. 1%, p<0.001; aOR:4.6 [95% CI:3.5-6.1]), cardiogenic shock (3.68% vs. 1.6%, p<0.001; aOR:2 [95% CI:1.5-2.6]), sepsis (1.9% vs. 0.63%, p<0.001; aOR:5.2 [95% CI:3.3-8.1]), vascular complications (2.8% vs. 0.8%, p<0.001; aOR:4 [95% CI:2.8-5.7]), pneumothorax (2.7% vs. 0.5%, p<0.001; aOR:6.9 [95% CI:4.7-10.3]), Left Bundle Branch Block (LBBB, 16.8% vs. 10.6%, p<0.001; aOR:3.2 [95% CI:2.8-3.7]), and more frequently required Intra-aortic balloon pump placement (IABP) placement (1.4% vs. 0.3%, p<0.001; aOR:4.4 [95% CI:2.7-7.1]) compared to ASA.

Compared to patients who underwent SM, those who underwent ASA had higher post-

procedure complete heart block (12.7% vs. 16.1%, p<0.001; aOR:1.2 [95% CI:1.1-1.4]),

2nd-degree AV Block (0.6% vs. 1.6%, p<0.001; aOR:2 [95% CI:1.4-3]), Right Bundle

Branch Block (RBBB, 1.8% vs. 10.6%, p<0.001; aOR:6.4 [95% CI:5.3-7.8]), ventricular

tachycardia (7.9% vs. 16%, p<0.001; aOR:2 [95% CI:1.8-2.3]), SVT (3.8% vs. 5.8%,

p<0.001; aOR:1.4 [95% CI:1.2-1.7]), and more commonly required pacemaker (8.4% vs.

10.9%, p<0.001; aOR:1.4 [95% CI:1.2-1.6]) or ICD insertion (6% vs. 6.5%, p<0.001;

aOR:1.3 [95% CI:1.1-1.5]).

There was no difference in rates of cardiac arrest (2.4% vs. 1.9%, p=0.002), ACS (2.4%

vs. 3.1%, p=0.119), Ventricular fibrillation/Ventricular Flutter (2.9% vs. 2%, p<0.74)

intra-operative and post-operative bleeding (3.3% vs. 2.5%, p=0.039), Gastrointestinal

bleeding (0.9% vs. 1%, p=0.117), or requiring cardioversion (6% vs. 7.6%, p=0.484)

between the compared groups.

Association between post-procedure SM vs. ASA inpatient mortality

Combining data from the studied years (2011-2019), patients undergoing SM had

higher inpatient all-cause mortality (2.5% vs. 1.3%, p<0.001) that remained significant

beyond adjustment for demographic factors and comorbidities (aOR:2.2 [95% CI:1.7-

10

2.9]).

Discussion

This nationwide retrospective analysis studying the outcomes after SM and ASA in patients with oHCM from 2011 to 2019 evidenced several essential findings that intend to better prepare the physician and the patient on the unique post-procedure expectations and the most common complications of each septal reduction intervention, thus facilitating and providing a basis for shared decision-making at the time of procedure and patient selection.

First, we found that the all-cause mortality after SM (2.5%) was higher than prior reports from single center-high volume experiences, where low postoperative mortality (<1%)^{5,9,10,11,12} is described, and similar to the volume-unadjusted report from the Society of Thoracic Surgeons Adult Cardiac Surgery Database¹³. We report a post-ASA mortality rate of 1.3%, which is similar to prior reports from the Mayo Clinic (1.4%)¹⁴ and higher than studies from the Euro-Alcohol Septal Ablation Registry (0.6%)¹⁵.

Our data supports findings suggesting that invasive SRTs are associated with increased

mortality when performed in centers with limited experience and low procedural

volume.^{5,13,15,16}

We also describe a higher incidence of post-procedure complications after SM,

including ischemic stroke, AKI, VSD, cardiogenic shock, requiring IABP support, sepsis,

vascular complications, LBBB, and pneumothorax compared to ASA.

One of the common complications after ASA is new onset conduction abnormalities 17,18.

which we also describe and can be attributed to the nature of the procedure itself.

Ventricular tachycardia was the most common arrhythmia reported (16%). The second

most common arrhythmia was the development of a RBBB- attributed to the superior

location of the fibers in the ventricular septum supplied by the first septal perforator-

although we found the incidence of the latter to be lower (10.6%) than reported in prior

studies (58-68%)^{19,20}. Since RBBB commonly occurs in cases of ASA¹⁷, the risk of

complete Atrio Ventricular Block (AVB) is highest in patients with preexisting LBBB.

As previously described 17,18, we found a higher post-ASA need for pacemaker or ICD

implantation (combined 17.4%).

Prior concerns regarding ventricular fibrillation/flutter related to post-ASA septal scar are

not reflected in more recent reports^{5,21,22}, results which we also describe, reporting no

difference (2.9% vs. 2%, p=0.74) when comparing both procedures.

There are several limitations present in our study: 1. This retrospective study from a

large inpatient database can lead to underrepresentation or overrepresentation of the

volume of procedures or co-morbid diagnosis. 2. The NIS database provides only in-

hospital outcomes; thus, our findings do not reflect the long-term hemodynamic or

clinical outcomes or the need for additional hospitalizations or procedures. 3. We cannot

assess for LVOT gradient or improvement in symptoms after the procedure. 4. Our

analysis included data from multiple hospitals nationwide that is not stratified according

to procedure volume as done in reports from specialized centers.

We recognize the above limitations and that many HCM recommendations are based

on observational data or expert opinion. Comparing both procedures requires larger

randomized trials, which might not be feasible considering the low event rates and slow

disease progression in HCM. Thus, reports from larger datasets like the NIS can be

useful in providing insight on the pros and cons of the available SRT procedures.

Conclusion

This nationwide analysis reports that patients undergoing SM had higher in-hospital

mortality and periprocedural complications than those undergoing ASA. Patients who

underwent ASA had more post-procedure conduction abnormalities and pacemaker or

ICD implantation requirements. Comparing both procedures with larger randomized

trials might not be feasible, and reports from larger datasets can provide insight into

post-procedure expectations, expected complications of septal reduction interventions,

and provide a foundation to assist in shared decision-making during procedure and

13

patient selection.

Acknowledgements

We would like to thank the Cardiovascular Department at Jackson Memorial Hospital and the University of Miami for their contributions in developing and completing this project.

Sources of Funding

The authors confirm no public or private sources of funding for the work presented in this manuscript.

Disclosure

The authors confirm no relationship with industry or disclosures for the work presented in this manuscript.

References

- Maron BJ. Clinical course and management of hypertrophic cardiomyopathy.
 New England Journal of Medicine. 2018; 379:655-668.
- Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS.
 Hypertrophic cardiomyopathy: Present and future, with translation into contemporary cardiovascular medicine. Journal of the American College of Cardiology. 2014; 64:83-99.
- 3. Teekakirikul P, Zhu W, Huang HC, Fung E. Hypertrophic Cardiomyopathy: An Overview of Genetics and Management. Biomolecules. 2019; 9:878.
- 4. Maron BJ, Rowin EJ, Maron MS. Evolution of risk stratification and sudden death prevention in hypertrophic cardiomyopathy: Twenty years with the implantable cardioverter-defibrillator. Heart Rhythm. 2021; 18:1012-1023.
- 5. Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients with Hypertrophic Cardiomyopathy: A

- Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020; 142:e558-e631.
- 6. Nishimura R, Otto C, Bonow R, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease. J Am Coll Cardiol. 2017; 70:252-289.
- 7. Zheng, R, Dong, Y, Wu, S, et al. Conduction system pacing following septal myectomy: insights into site of conduction block. J Cardiovasc Electrophysiol. 2022; 33: 437- 445.
- 8. Sherrid MV, Massera D, Swistel DG. Surgical Septal Myectomy and Alcohol Ablation: Not Equivalent in Efficacy or Survival. J Am Coll Cardiol. 2022; 79:1656-1659.
- 9. Williams LK, Rakowski H. Surgical myectomy for hypertrophic obstructive cardiomyopathy. Circulation. 2013; 128:193-197.
- 10. Smedira NG, Lytle BW, Lever HM, Rajeswaran J, Krishnaswamy G, Kaple RK, et al. Current effectiveness and risks of isolated septal myectomy for hypertrophic obstructive cardiomyopathy. The Annals of Thoracic Surgery. 2008; 85:127-133.
- 11. Wong L-Y, Alver N, Dewey EN, Bhamidipati C, Lantz G, Tibayan FA, et al. Septal myectomy for obstructive hypertrophic cardiomyopathy in the elderly. The Annals of Thoracic Surgery. 2022; 113:1477-1481.
- 12. Maron BJ, Dearani JA, Ommen SR, Maron MS, Schaff HV, Gersh BJ, et al. The case for surgery in obstructive hypertrophic cardiomyopathy. Journal of the American College of Cardiology. 2004; 44:2044-2053.

- 13. Holst KA, Schaff HV, Smedira NG, Habermann EB, Day CN, Badhwar V, et al. Impact of hospital volume on outcomes of Septal Myectomy for Hypertrophic Cardiomyopathy. The Annals of Thoracic Surgery. 2022; 114:2131-2138.
- 14. Sorajja P, Valeti U, Nishimura RA, Ommen SR, Rihal CS, Gersh BJ, et al. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation. 2008; 118:131-139.
- 15. Veselka J, Faber L, Liebregts M, Cooper R, Januska J, Krejci J, et al. Outcome of alcohol septal ablation in mildly symptomatic patients with hypertrophic obstructive cardiomyopathy: A long-term follow-up study based on the euro-alcohol septal ablation registry. Journal of the American Heart Association. 2017;6: e005735.
- 16. Polanco Antonio R, D'Angelo A, Shea N, Yu Sarah N, Chiang Yuting P, Shimada Y, et al. Impact of septal myectomy volume on mitral-valve replacement rate in hypertrophic cardiomyopathy patients. Cardiology. 2020; 145:161-167.
- 17. El-Sabawi B, Nishimura RA, Barsness GW, Cha Y-M, Geske JB, Eleid MF. Temporal occurrence of arrhythmic complications after alcohol septal ablation. Circulation: Cardiovascular Interventions. 2020;13: e008540.
- 18. Sorajja P. 18 Septal ablation for hypertrophic obstructive cardiomyopathy. In: Kern MJ, Sorajja P, Lim MJ, eds. The interventional cardiac catheterization handbook (fourth edition). Elsevier; 2018:448-458.
- 19. Valeti US, Nishimura RA, Holmes DR, Araoz PA, Glockner JF, Breen JF, et al.

 Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive

- cardiomyopathy. Journal of the American College of Cardiology. 2007; 49:350-357.
- 20. Rastegar H, Boll G, Rowin EJ, Dolan N, Carroll C, Udelson JE, et al. Results of surgical septal myectomy for obstructive hypertrophic cardiomyopathy: The tufts experience. Annals of Cardiothoracic Surgery. 2017; 6:353-363.
- 21.Nguyen A, Schaff HV, Hang D, Nishimura RA, Geske JB, Dearani JA, et al. Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy: A propensity score-matched cohort. The Journal of Thoracic and Cardiovascular Surgery. 2019; 157:306-315.e303.
- 22. Batzner A, Pfeiffer B, Neugebauer A, Aicha D, Blank C, Seggewiss H. Survival after alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy. Journal of the American College of Cardiology. 2018; 72:3087-3094.

Tables

Table 1.

Baseline characteristics of patients with Hypertrophic Cardiomyopathy with

Outflow Tract Obstruction who underwent Septal Myectomy vs. Alcohol Septal

Ablation

Variable	Septal Myectomy	Alcohol Septal	P-value*	
	(N=10,781)	Ablation (N=6,464)		
Baseline characteristics				
Age in years	58.9 ± 14.1	63.3 ± 13.6	<0.001	
Female Gender	4,805 (44.6%)	2,960 (45.8%)	0.118	
White Race	9,039 (83.8%)	5,161 (79.8%)	<0.001	
Hypertension	7,450 (72%)	4,475 (72.2%)	0.960	
Diabetes Mellitus	1,895 (17.7%)	1,213 (18.8%)	0.055	

Atrial Fibrillation	4,643 (43%)	3,058 (47.3)	<0.001
Atrial Flutter	688 (6.4%)	1,325 (18.9%)	<0.001
Tobacco use	4,025 (37.3%)	1,992 (30.8%)	<0.001
Alcohol use	243 (2.3%)	84 (1.3%)	<0.001
Substance use	165 (1.5%)	45 (0.7%)	<0.001
Hyperlipidemia	5,784 (57.2%)	3,477 (57.7%)	0.508
Obesity	3,148 (29.2%)	1,229 (19%)	<0.001
Anemia	299 (3.4%)	194 (3.8%)	<0.001
Obstructive Sleep Apnea	2,200 (20.4%)	1,349 (20.9%)	0.468
Presence of pacemaker	359 (3.3%)	521 (8.1%)	<0.001
Presence of an Implantable	1,343 (12.5%)	1,353 (20%)	<0.001
Cardioverter Defibrillator			
Thrombocytopenia	2,735 (25.4%)	238 (3.7%)	<0.001
Heart Failure	4,568 (42.5%)	2,557 (39.6%)	<0.001
All prior strokes	526 (3.95%)	503 (7.8%)	<0.001
Coronary Artery Disease	3,832 (35.9%)	2,233 (34.7%)	<0.001
Peripheral Artery Disease	418 (4%)	165 (2.6%)	<0.001
Chronic Kidney Disease	1,126 (10.5%)	805 (12.5%)	<0.001
Chronic Obstructive	1,159 (10.9%)	842 (13.2%)	<0.001
Pulmonary Disease			
History of Myocardial	476 (4.4%)	416 (6.4%)	<0.001
Infarction			

Liver Disease and Cirrhosis	264 (2.5%)	200 (3.1%)	0.014
History of Percutaneous	654 (6%)	632 (9.8%)	<0.001
Coronary Intervention			
History of Coronary Artery	129 (1.2%)	140 (2.2%)	<0.001
Bypass Graft			
Pulmonary Hypertension	1,522 (14.1%)	644 (9.9%)	<0.001

^{*} A p-value <0.001 was considered statistically significant.

Table 2.

Mortality and In-hospital outcomes in patients with Hypertrophic Cardiomyopathy
with Outflow Tract Obstruction who underwent Septal Myectomy vs. Alcohol
Septal Ablation

Variable		Septal	Alcohol Septal	P-value*, aOR
		Myectomy	Ablation	[95% CI] [†]
		(N=10,781)	(N=6,464)	
N	/lortali	ity and In-Hosp	ital Outcomes	
All-cause mortality		278 (2.5%)	86 (1.3%)	<0.001;
				aOR: 2.2 [1.7-2.9]
Post-procedure Ca	ırdiac	259 (2.4%)	120 (1.9%	0.002
arrest				
Post-procedure isch	emic	243 (2.25%)	79 (1.2%)	<0.001;

stroke			aOR: 2.389 [1.8-
			3.2)
Post-procedure Cardiogenic	397 (3.68%)	101 (1.6%)	<0.001;
shock			aOR: 2 [1.5-2.6]
Acute Kidney Injury	1,232	474 (7.3%)	<0.001;
	(11.5%)		aOR: 1.9 [1.7-2.2]
Acute Coronary Syndrome	252 (2.4%)	196 (3.1%)	0.119
Intra-aortic Balloon Pump	147 (1.4%)	21 (0.3%)	<0.001;
Placement			aOR: 4.4 [2.7-7.1]
Sepsis	209 (1.9%)	40 (0.63%)	<0.001;
			aOR:5.2 [3.3-8.1]
Coronary Artery Bypass Graft	748 (6.9%)	15 (0.2%)	<0.001;
			aOR: 108 [45-263]
Intra and post operative	352 (3.3%)	160 (2.5%)	0.039
hemorrhage			
Gastrointestinal bleed	94 (0.9%)	66 (1%)	0.117
All major bleed	536 (5%)	305 (4.7%)	0.2
Cardioversion	642 (6%)	493 (7.6%)	0.484
Insertion of Pacemaker	910 (8.4%)	704 (10.9%)	<0.001;
			aOR: 1.4 [1.2-1.6]
Insertion of Implantable	645 (6%)	417 (6.5%)	<0.001;
Cardioverter Defibrillator			aOR: 1.3 [1.1-1.5]

Complete Heart Block	1,372	1,042 (16.1%)	<0.001;
	(12.7%)		aOR: 1.2 [1.1-1.4]
2 nd degree AV Block	65 (0.6%)	105 (1.6%)	<0.001;
			aOR: 2 [1.4-3]
Left Bundle Branch Block	1,811	400 (6.1%)	<0.001;
	(16.8%)		aOR: 3.2 [2.8-3.7]
Right Bundle Branch Block	195 (1.8%)	683 (10.6%)	<0.001;
			aOR: 6.4 [5.3-7.8]
Ventricular Fibrillation/	225 (2.9%)	130 (2%)	0.74
Ventricular flutter			
Ventricular Tachycardia	856 (7.9%)	1036 (16%)	<0.001;
			aOR:2 [1.8-2.3]
Supraventricular Tachycardia	408 (3.8%)	372 (5.8%)	<0.001;
			aOR: 1.4 [1.2-1.7]
Pneumothorax	295 (2.7%)	35 (0.5%)	<0.001;
			aOR: 6.9 [4.7-10.3]
Vascular complications	233 (2.8%)	45 (0.8%)	<0.001;
			aOR: 4 [2.8-5.7]
Ventricular Septal Defect	512 (4.8%)	65 (1%)	<0.001;
			aOR: 4.6 [3.5-6.1]

^{*} A p-value <0.001 was considered statistically significant.

[†] Multivariate logistic regression was used to estimate adjusted odds ratios (aOR) and 95% confidence intervals (95% CI). Our models were adjusted for age, sex, race, and statistically significant comorbidities

(Hypertension, Atrial fibrillation, Atrial Flutter, Tobacco use, Substance use, Heart Failure, Obesity, Peripheral artery Disease, Chronic Kidney Disease, Chronic Obstructive Pulmonary Disease, prior history of Myocardial Infarction, history of Percutaneous Coronary Intervention, history of Coronary Artery Bypass Graft, prior presence of Pacemaker or ICD, and Pulmonary Hypertension).